Work

Abstract 3305: Biochemical and cellular evaluation of HUNK inhibition by an FDA approved drug as potential therapeutic strategy for HER2+ breast cancer

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-3305

Authors: Safnas Farwin AbdulSalam, Mia M. Eason, Shuguang Liang, Alison Goupil, Anthony Acinapura, Maia Dominguez, Peter Gallagher, Yuan Wang, Jianghong Wu, Haiching Ma

Institutions: Reaction Biology Corporation (United States), Reaction Biology (Germany)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7148753286

Cites:

Cited by:

Related to: